Name: Tricaprilin
Synonyms: AC-1204 , Caprylic triglyceride
Therapy Type: Other
Target Type: Other (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 2/3)
Company: Accera, Inc.
Approved for: None


AC-1204 is the follow-up to Accera's AC-1202/Axona medical food product. It is a proprietary, oral formulation of caprylic triglyceride, which was designed to induce a mild chronic ketosis in order to improve mitochondrial metabolism. Regional reductions in cerebral glucose utilization are an early feature of Alzheimer's disease (Reiman et al., 2004). The rationale behind AC-1204 is to boost cellular metabolism in Alzheimer's by providing a fuel alternative to glucose. Caprylic acid is metabolized into so-called ketone bodies, such as acetoacetic acid and β-hydroxybutyric acid, which can be converted to acetyl-CoA to produce energy via the citric acid cycle.


Based on clinical experience with Accera's Axona, a medical food similar to AC-1204, this new formulation entered clinical evaluation in Phase 2/3.

In December 2012, Accera withdrew ALERT, a planned six-month Phase 2/3 trial it had previously registered (NCT01211782), reportedly because it was being redesigned. 

From March 2013 to October 2016, Accera conducted NOURISH AD, a multicenter, six-month efficacy trial with an optional six-month, open-label extension. This trial enrolled 418 patients with mild to moderate AD at 82 locations in the United States. It compared the effect of once-daily administration of 40 mg of AC-1204 containing 20 mg of the active ingredient caprylic triglyceride to placebo on the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADASCog) in ApoE4 non-carriers. As secondary outcomes, the trial used additional cognitive, clinical, and global measures in ApoE4 non-carriers; other outcomes include overlapping measures in ApoE4 carriers plus still more cognitive and clinical measures in both carriers and non-carriers. 

In 2016, Accera started three Phase 1 studies of AC-1204 in a total of 52 healthy volunteers. One compares serum ketone body levels after administration of AC-1204 versus caprylic triglyceride oil, as well as interactions with a high-fat diet; one compares serum ketone body generation after AC-1204 mixed in water or AC-1202 in water, versus AC-1201 in Ensure; and one compares ketone body generation after a single dose of AC-1204 to similar formulations, including AC-1202. Also in 2016, Accera conducted a pilot safety study of AC-1204 in 10 people with amyotrophic lateral sclerosis.

On February 28, 2017, Accera announced that the NOURISH-AD trial had failed to detect a statistially significant difference between AC-1204 and placebo on the ADAS-cog (see company press release).

For all clinical trials on AC-1204, see

Clinical Trial Timeline

  • Phase 2/3
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Sponsor Clinical Trial 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Accera, Inc. NCT01741194


No Available Comments

Make a Comment

To make a comment you must login or register.


Therapeutics Citations

  1. Ketasyn

Paper Citations

  1. . Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9. PubMed.

External Citations

  1. see company press release

Further Reading

No Available Further Reading